{
    "eid": "2-s2.0-85161428942",
    "title": "Survival rates of adult patients with Hodgkin lymphoma who underwent ABVD versus escalated BEACOPP in a resource-limited country: An observational study",
    "cover-date": "2023-08-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Cancer Research",
            "@code": "1306",
            "@abbrev": "BIOC"
        }
    ],
    "keywords": [
        "adult",
        "advance-stage cancer",
        "chemotherapy",
        "Hodgkin disease",
        "life expectancy",
        "limited resource country"
    ],
    "authors": [
        "Tawatchai Suwanban",
        "Supat Chamnanchanunt",
        "Pravinwan Thungthong",
        "Chajchawan Nakhahes",
        "Kunapa Iam-arunthai",
        "Tananchai Akrawikrai",
        "Udomsak Bunworasate"
    ],
    "citedby-count": 0,
    "ref-count": 36,
    "ref-list": [
        "Adolescent and young adult Hodgkin lymphoma: raising the bar through collaborative science and multidisciplinary care",
        "Sociodemographic disparities in the occurrence of medical conditions among adolescent and young adult Hodgkin lymphoma survivors",
        "Resources-stratified guidelines for classical Hodgkin lymphoma",
        "Analysis of 1983 cases of malignant lymphoma in Thailand according to the World Health Organization classification",
        "Malignant lymphoma in Thailand: changes in the frequency of malignant lymphoma determined from a histopathologic and immunophenotypic analysis of 425 cases at Siriraj hospital",
        "Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's lymphoma study group trial HD5",
        "ABVD vs BEACOPP escalated in advanced-stage Hodgkin's lymphoma: results from a multicenter European study",
        "ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo studio Dei Linfomi trial",
        "ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned",
        "ABVD (8 cycles) versus BEACOPP (4 escalated cycles >/= 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial",
        "Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in stage III to IV, international prognostic score >/= 3, high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 intergroup trial",
        "Advanced-stage Hodgkin lymphoma: have effective therapy and modern imaging changed the significance of bulky disease?",
        "COVID-19 infection in cancer patients: how can oncologists deal with these patients?",
        "Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin study group HD7, HD8, HD10, and HD11 trials",
        "PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin study group",
        "Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin study group HD14 trial",
        "Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial",
        "Comparison of 36 Gy, 20 Gy, or no radiation therapy after 6 cycles of EBVP chemotherapy and complete remission in early-stage Hodgkin lymphoma without risk factors: results of the EORT-GELA H9-F intergroup randomized trial",
        "Hodgkin lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up",
        "A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425",
        "Survival and long-term toxicities of pediatric Hodgkin lymphoma after combined modality treatment: a single institute experience",
        "Role of the gallium scan in Hodgkin's disease",
        "A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era",
        "PET-CT for staging and early response: results from the response-adapted therapy in advanced Hodgkin lymphoma study",
        "Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin lymphoma: predictive role before treatment and early assessment after two courses of ABVD",
        "Hodgkin lymphoma of the elderly patients: a retrospective multicenter analysis from the polish lymphoma research group",
        "Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma",
        "Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial",
        "Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma",
        "Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma",
        "Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial",
        "Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma",
        "Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: long-term results of the GITIL/FIL HD 0607 trial",
        "Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin study group"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60199573",
            "affilname": "Faculty of Tropical Medicine, Mahidol University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199573",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Pathum Thani",
            "@id": "60023366",
            "affilname": "Rangsit University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60023366",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Rajavithi Hospital",
        "Thai Society of Hematology",
        "Mahidol University"
    ]
}